Siemens and Pfizer Collaborate on Companion Diagnostics
Siemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer
Siemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer to design, develop and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. That pipeline includes 31projects in Phase I, 24 in Phase II, and 20 in Phase III as of November 2013. Under the agreement, Siemens will be one of Pfizer’s collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies. Siemens Clinical Laboratory (SCL), its "high-complexity" testing laboratory focused on advancing personalized medicine, will develop these companion diagnostic tests. “Companion diagnostics are an important enabler of targeted therapies for patients,” said John Hubbard, Senior Vice President and Worldwide Head of Development Operations at Pfizer.
Siemens’ is known for providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development. The agreement is to leverage these capabilities.
You can read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
